Citation Impact
Citing Papers
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
2009 Standout
Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients
2001 Standout
A Gene Expression Signature that Can Predict the Recurrence of Tamoxifen-Treated Primary Breast Cancer
2008
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up
1999
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
2000
Borderline HER‐2 breast cancer cases: Histochemical versus real‐time PCR analysis and impact of different cut‐off values
2007
Molecular Markers for Predicting Response to Tamoxifen in Breast Cancer Patients
2000
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
The relationship between prognostic and predictive factors in the management of breast cancer
1998
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer
2004
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
2014 Standout
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance
2000
Range of antinuclear antibodies in “healthy” individuals
1997
PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo
1995 Standout
Breast cancer
2016 Standout
Sjögren's syndrome
2005 Standout
Oncogenic kinase signalling
2001 StandoutNature
NF-κB in cancer: from innocent bystander to major culprit
2002 Standout
The Clinical Significance of Epidermal Growth Factor Receptor (EGF-R) in Human Breast Cancer: A Review on 5232 Patients*
1992
TGF-β signaling in tumor suppression and cancer progression
2001 Standout
TGFβ signalling in context
2012 Standout
Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer
1998
The landscape of long noncoding RNAs in the human transcriptome
2015 Standout
Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas
1994
Targeting cancer with small molecule kinase inhibitors
2008 Standout
Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer
1995
The urokinase-type plasminogen activator system in cancer metastasis: A review
1997 Standout
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
2001 Standout
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Uterine fibroids
2001 Standout
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
2005
The microenvironment of the tumour–host interface
2001 StandoutNature
p53 determination alongside classical prognostic factors in node-negative breast cancer: An evaluation at more than 10-year follow-up
2000
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Epstein–Barr virus: 40 years on
2004 Standout
Tumour-educated macrophages promote tumour progression and metastasis
2004 Standout
Tumor angiogenesis in node-negative breast carcinomas ? relationship with epidermal growth factor receptor, estrogen receptor, and survival
1994
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay
1996
Expression of the fibroblast growth factor receptor in women with leiomyomas and abnormal uterine bleeding
1997
Protein tyrosine kinases and cancer
1997
The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients
1994
Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer.
1997
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Prognostic molecular markers in early breast cancer
2004
Cornerstones of CRISPR–Cas in drug discovery and therapy
2016 StandoutNobel
Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and theor relation to estradiol receptor (ER) status
1997
MYC oncogenes and human neoplastic disease
1999
Genes that mediate breast cancer metastasis to lung
2005 StandoutNature
Free circulating mRNA in plasma from breast cancer patients and clinical outcome
2008
The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
1998
Breast cancer metastasis: markers and models
2005 Standout
Sequence and structure-based prediction of eukaryotic protein phosphorylation sites
1999 Standout
TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data
2015 Standout
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a standardized flow cytometric study.
2001
A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase
1994 Science
Atomically Precise Colloidal Metal Nanoclusters and Nanoparticles: Fundamentals and Opportunities
2016 Standout
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
2003 Standout
Gold Nanoparticles for In Vitro Diagnostics
2015
Repeated observation of breast tumor subtypes in independent gene expression data sets
2003 Standout
New Strategies for Fluorescent Probe Design in Medical Diagnostic Imaging
2009 Standout
Breast Cancer Treatment
2019 Standout
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Urokinase-type plasminogen activator and malignancy
1993
Hypoxia-Inducible Factor 1 and Dysregulated c-Myc Cooperatively Induce Vascular Endothelial Growth Factor and Metabolic Switches Hexokinase 2 and Pyruvate Dehydrogenase Kinase 1
2007 StandoutNobel
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
2001 Standout
PROGNOSTIC MARKERS IN BLADDER CANCER: A CONTEMPORARY REVIEW OF THE LITERATURE
1998
Metabolic reprogramming and cancer progression
2020 StandoutScience
Reactivity with A monoclonal antibody to Epstein-Barr virus (EBV) nuclear antigen 1 defines a subset of aggressive breast cancers in the absence of the EBV genome.
2003
Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma
2001 StandoutNobel
S-Phase Fraction and Urokinase Plasminogen Activator Are Better Markers for Distant Recurrences Than Nottingham Prognostic Index and Histologic Grade in a Prospective Study of Premenopausal Lymph Node–Negative Breast Cancer
2001
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
2014 Standout
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Dissemination Risk Index Based on Plasminogen Activator System Components in Primary Breast Cancer
1999
A role for the TGFβ-Par6 polarity pathway in breast cancer progression
2009
Works of S Romain being referenced
c-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse
1992
Prognostic value of a solubilized fraction of EGF receptors in primary breast cancer using an immunoenzymatic assay ? a retrospective study
1994
Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study
1999
Correlation of erbB-2 gene amplification with low levels of estrogen and/or progesterone receptors in primary breast cancer : do erbB-2 products delineate hormone-independent tumors?
1989
Determination of oestrogen receptors by enzyme immunoassay. Technical differences between laboratories and their consequences
1994
Prognostic value of epidermal growth factor receptor in node-positive breast cancer
1989
steroid receptor distribution in 47 892 breast cancers. A collaborative study of 7 European laboratories
1995
Biochemical and immunohistochemical multiparametric analysis of steroid receptors and growth factor receptors in human normal endometrium in spontaneous cycles and after the induction of ovulation
1994
Determination of TGFβ1 protein level in human primary breast cancers and its relationship with survival
2006
Multiparametric Prognostic Evaluation of Biological Factors in Primary Breast Cancer
1992
Frequency and genome load of Epstein–Barr virus in 509 breast cancers from different geographical areas*
2001
Optimizing flow cytometric DNA ploidy and S‐phase fraction as independent prognostic markers for node‐negative breast cancer specimens
2001
Thymidine Kinase as a Proliferative Marker: Clinical Relevance in 1,692 Primary Breast Cancer Patients
2001
Reliability and discriminant validity of HER2 gene quantification and chromosome 17 aneusomy analysis by real-time PCR in primary breast cancer
2006
Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy.
2001
[Standardization and quality control in the evaluation of proliferation parameters in T1T2, N0N1, M0 breast cancer: multicentric retrospective study II. DNA-ploidy and S-phase fraction].
1999
Comparative study of four extraction procedures for urokinase type plasminogen activator and plasminogen activator inhibitor-1 in breast cancer tissues.
1995
[Reevaluation of indications for adjuvant hormone therapy in primary breast cancer with high metastatic risk].
1991
[Cathepsin D: an independent prognostic factor in cancer of the breast].
1990